OmniComm Systems® Expands Presence in Japan and Philippines

June 16, 2015
Company Press Release

Applied Clinical Trials

Fort Lauderdale, FL, June 15, 2015 - OmniComm Systems, Inc. (OmniComm) (OTCQB: OMCM), a global leading provider of clinical data management technology, announces the selection of Promasys® EDC by Integrated Development Associates (IDA), a Tokyo-based Pan Asian drug development company to run clinical trials in Japan and the Philippines. Japan represents the second largest pharmaceutical market in the world whereas the Philippines is one of the fastest growing markets.

“As IDA grows, we see not only the need to integrate Japan into large global studies but also the need to efficiently deliver turn-key Phase I ethnic bridging studies and stand-alone local Japan and Pan Asian clinical trials for clients,” says John Winebarger, president and CEO, IDA. “The Promasys system is an important tool that will now allow us to offer our clients with data management and EDC services in a highly reliable and cost efficient manner.”

After a thorough evaluation process of various commercially available technologies, IDA selected Promasys technology to manage its clinical data management activities. Overall Promasys was deemed to be best suited in terms of ease of use, fast study build, data quality and integrity and subject recruitment.

“OmniComm already has a strong presence in East Asia with an increasing number of customers in China, Korea and Japan” says Wolf Ondracek, senior vice president of Asian and Academic Markets at OmniComm. “Now that IDA have selected Promasys as the solution for their local and international data capture and data management needs, we will not only further strengthen our presence in the strategic Japanese market, but also enter the Philippines which is a new but important territory. We are proud that our software will be used at the Phase I facilities within the prestigious De La Salle Health Sciences Institute in Dasmariñas, as well as with IDA Japanese and their Pan Asian Phase I-IV clinical trials.” 

Related Content:

News